Stryker Corporation $SYK Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 12.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,038 shares of the medical technology company’s stock after purchasing an additional 5,623 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Stryker were worth $18,867,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in Stryker by 23.6% during the second quarter. Janney Montgomery Scott LLC now owns 85,479 shares of the medical technology company’s stock worth $33,818,000 after buying an additional 16,322 shares in the last quarter. Capital Investment Advisors LLC grew its position in Stryker by 1.8% in the second quarter. Capital Investment Advisors LLC now owns 3,299 shares of the medical technology company’s stock worth $1,305,000 after buying an additional 59 shares during the last quarter. Truist Financial Corp increased its holdings in shares of Stryker by 3.5% in the second quarter. Truist Financial Corp now owns 107,995 shares of the medical technology company’s stock valued at $42,726,000 after buying an additional 3,656 shares in the last quarter. Finally, Cooper Financial Group lifted its position in shares of Stryker by 90.3% during the 2nd quarter. Cooper Financial Group now owns 2,205 shares of the medical technology company’s stock valued at $872,000 after acquiring an additional 1,046 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

More Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly beat: Stryker reported adjusted Q4 EPS $4.47 and revenue $7.17B, topping consensus on both measures — a clear near‑term positive for revenue and profitability trends. Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Raised profit outlook: Management raised its full‑year profit forecast, citing strong implant and capital product demand — a catalyst for forward earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Solid full‑year momentum and guidance: FY2025 adjusted EPS and margins expanded (adjusted EPS $13.63; adjusted operating margin +100 bps year) and management guided 2026 organic net‑sales growth ~8.0%–9.5% with adjusted EPS $14.90–$15.10 — supports medium‑term upside. Stryker reports 2025 operating results and 2026 outlook
• Neutral Sentiment: Analyst/street context: Several firms maintain positive ratings (e.g., Piper Sandler reaffirmed a Buy), and sell‑side median targets remain well above the current price — supports sentiment but may already be priced in. Piper Sandler Remains a Buy on Stryker (SYK)
• Neutral Sentiment: Conference call / details ahead: Management held an earnings call and provided granular segment math and non‑GAAP reconciliations — useful for modeling but unlikely to shift the stock absent new guidance tweaks. Press release & conference details
• Negative Sentiment: Mixed segment dynamics: MedSurg & Neuro showed double‑digit growth, but spinal implants and some orthopaedics subcategories remain weak or volatile — a potential drag on sustained top‑line upside. Stryker Reports Strong Q4 and Full-Year 2025 Results
• Negative Sentiment: One‑offs and legacy charges: Prior goodwill impairments, tax adjustments and other special items still affect GAAP comparisons and introduce modeling uncertainty — some investors may be trimming positions until recurring earnings visibility is clearer. Full release: reconciliations and note on adjustments
• Negative Sentiment: Valuation and profit‑taking risk: SYK trades at a premium P/E (~46 on reported metrics) and recent insider selling activity may encourage short‑term profit‑taking despite the beat. Analyst comparison & metrics

Insider Transactions at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the sale, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This represents a 9.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 522,118 shares of company stock valued at $185,381,932. 5.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. BTIG Research restated a “buy” rating and issued a $410.00 target price on shares of Stryker in a report on Friday, November 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of Stryker in a research note on Monday, December 22nd. Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a research note on Tuesday. Raymond James Financial raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 target price on the stock in a research report on Tuesday, January 6th. Finally, TD Cowen lowered shares of Stryker from a “buy” rating to a “hold” rating and set a $387.00 price target on the stock. in a report on Monday. Twelve equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $425.94.

Stryker Trading Down 1.0%

NYSE:SYK opened at $354.39 on Friday. The stock has a market cap of $135.52 billion, a PE ratio of 46.57, a price-to-earnings-growth ratio of 2.29 and a beta of 0.89. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13. The stock’s 50-day moving average is $359.38 and its two-hundred day moving average is $371.95.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The business had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.12 billion. During the same period last year, the company posted $4.01 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, December 31st. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. This is an increase from Stryker’s previous quarterly dividend of $0.84. Stryker’s dividend payout ratio is presently 46.25%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.